Beta Pharma, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Princeton NJ United States (1996)

Organization Overview

First Clinical Trial
2015
NCT02375022
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Beta Pharma, Inc. | Beta Pharma Shanghai | Beta Pharma (Suzhou) Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 9